-
MicroPort CRM Receives NMPA Approval for Next-Generation MRI-Safe Implantable Cardiac Pacing System
•
MicroPort Scientific Corp. (HKG: 0853), a leading Shanghai-based medical device company, has announced that its France-based subsidiary MicroPort Cardiac Rhythm Management Limited (MicroPort CRM) has received a market license from the National Medical Products Administration (NMPA) for its next-generation intravenous magnetic resonance conditionally safe implantable cardiac pacing system. The product…
-
Jiangsu Wuzhong Pharmaceutical Partners with SPH KDL Health to Boost Aesthetics Product AestheFill
•
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a leading Chinese pharmaceutical company, has announced a strategic partnership agreement with domestic firm SPH KDL Health. The collaboration aims to enhance the marketing efforts of Wuzhong Pharmaceutical’s medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill. The partnership encompasses commercial distribution, expansion of…
-
Healthstar Medical Commences Phase III Clinical Trial for KC1036 in Esophageal Cancer
•
Healthstar Medical Development Co., Ltd (SHA: 603590), a Beijing-based pharmaceutical company, has announced the first patient dosing in a Phase III clinical study for its drug candidate KC1036, which is aimed at treating patients with advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks a significant milestone in…
-
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
•
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with South Korean firm Myung In Pharm. Under the agreement, Myung In Pharm has been granted commercialization rights to Luye’s rivastigmine twice-weekly transdermal patch (LY03013) in South Korea. The drug is indicated for the treatment of…
-
Abbisko Therapeutics Secures $70 Million Upfront Payment in Licensing Deal with Merck KGaA
•
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has declared the successful conclusion of the initial phase of a licensing agreement with Merck KGaA, concerning its proprietary colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). As part of this agreement, Abbisko has received an upfront payment of USD 70…
-
Joincare Pharmaceuticals Gets Green Light for Semaglutide Biosimilar Clinical Trial
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that it has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for its biosimilar version of Denmark’s major pharmaceutical company, Novo Nordisk’s semaglutide. Joincare is progressing with the development of this product candidate,…
-
Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
•
Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the first three quarters of its fiscal year 2023, concluding on December 31, 2023. The company has experienced a modest 2.1% year-on-year (YOY) increase in global revenues, totaling JPY 1,189 billion (USD 8 billion) for the…
-
CSPC Pharmaceutical’s rhTNK-tPA Gets NMPA Approval for Acute Ischemic Stroke Treatment
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has approved a supplementary market approval filing for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA). The drug is now approved for use as a thrombolytic…
